Director/PDMR Shareholding
("Renalytix" or the "Company")
Director/PDMR Dealing
Following completion of the purchase,
For further information, please contact:
Renalytix plc |
||
|
Via Walbrook PR |
|
|
|
|
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
|
|
|
|
|
|
|
Investec Bank plc (Joint Broker) |
Tel: 020 7597 4000 |
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|
|
Mob: 07980 541 893 / 07584 391 303 |
|
About KidneyIntelX
KidneyIntelX is a first-of-kind solution that enables early-stage diabetic kidney disease (DKD) progression risk assessment by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems, and employs a proprietary algorithm to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.
About Renalytix
The information contained in this notification is disclosed in accordance with the requirements of MAR.
1 |
Details of the person discharging managerial responsibilities/person closely associated
|
||
a) |
|
|
|
2 |
Reason for the notification
|
||
a) |
Position/status |
Non-Executive Director
|
|
b) |
Initial notification /Amendment
|
Initial Notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||
a) |
|
|
|
b) |
Legal Entity Identifier |
213800NTOH3FK3WER551
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
a) |
Description of the financial instrument, type of instrument
Identification code |
ADS', each ADS representing two Ordinary Shares of
US75973T1016
|
|
b) |
Nature of the transaction |
Purchase of ADS'
|
|
c) |
Currency
|
US Dollar |
|
d) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
3,000 ADS (representing 6000 Ordinary Shares) |
||
e) |
Aggregated information - Aggregated volume - Price - Aggregated total
|
3,000 ADS (representing 6,000 Ordinary Shares) |
|
f) |
Date of the transaction |
|
|
g) |
Place of the transaction |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the